Selected publications
-
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell.
2018
Academic Article
GET IT
Times cited: 178 -
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Cancer Biology and Therapy.
2010
Academic Article
GET IT
Times cited: 36 -
Tumor-selective response to antibody-mediated targeting of α
v β3 integrin in ovarian cancer. Neoplasia (United States). 2008 Academic Article GET IT
Times cited: 86 -
Targeting Aurora kinase with MK-0457 inhibits ovarian cancer growth.
Clinical Cancer Research.
2008
Academic Article
GET IT
Times cited: 53 -
HLA class i antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
Clinical Cancer Research.
2008
Academic Article
GET IT
Times cited: 98 -
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
Journal of the National Cancer Institute.
2008
Academic Article
GET IT
Times cited: 189 -
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Clinical Cancer Research.
2007
Academic Article
GET IT
Times cited: 130 -
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 101 -
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 66 -
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
Clinical Cancer Research.
2007
Academic Article
GET IT
Times cited: 69 -
EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Cancer.
2007
Academic Article
GET IT
Times cited: 80 -
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Cancer Research.
2007
Academic Article
GET IT
Times cited: 118 -
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
Cancer Biology and Therapy.
2006
Academic Article
GET IT
Times cited: 81 -
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Journal of the National Cancer Institute.
2006
Academic Article
GET IT
Times cited: 100 -
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
Cancer Biology and Therapy.
2006
Academic Article
GET IT
Times cited: 14 -
Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma.
Cancer Biology and Therapy.
2006
Academic Article
GET IT
Times cited: 76 -
Antiangiogenic and antitumor effects of Src inhibition in ovarian carcinoma.
Cancer Research.
2006
Academic Article
GET IT
Times cited: 68 -
Focal adhesion kinasetargeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 266 -
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Nature Medicine.
2006
Academic Article
GET IT
Times cited: 676 -
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 141 -
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Journal of Clinical Oncology.
2006
Academic Article
GET IT
Times cited: 57 -
Stress hormone-mediated invasion of ovarian cancer cells.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 318